Endovascular and Interventional Radiology Consultant Bella Huasen (Preston, United Kingdom) stopped by the CX studio to chat about the upcoming Charing Cross Symposium in April 2023.
Like all of us, she is looking forward to CX – to networking, debating and reaching consensus on peripheral arterial topics. We will be welcoming over 2,500 delegates, virtually and in-person, from over 80 countries and we have received more than “300 abstracts submissions with first-time data including super high-volume centres.” Dr Huasen shines a spotlight on the “amazing new first-time BASIL-2 data coming.”
Join Dr Huasen and the rest of the CX community in the Hilton London Metropole 25–27 April 2023 by registering today!
What to expect from BASIL-2 data at CX 2023:
BASIL-2 is a multi-centre randomised controlled trial to find out if a ‘vein bypass first’ or a ‘best endovascular first’ revascularisation strategy is best, in terms of either clinical or cost-effectiveness, for severe limb ischaemia due to infra-popliteal disease.
CX 2023 will be the first to report on the results of the trial, as well as;
- Background to BASIL-2
- BASIL-2 methodology including statistics
- BASIL-2 clinical results
- BASIL-2 discussion
- BASIL-2 conclusion
- Audience participation and polling
